At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
nab-Paclitaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial With Nab-Paclitaxel (ABRAXANE®) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subjects With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2 (ABOUND.PS2)
In Brief
A Phase 2 clinical trial evaluating nab-Paclitaxel and Carboplatin for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 40 participants across 8 sites.
Detailed Summary
4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4 cycles.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartApr 2015
Primary CompletionFeb 2017
TodayJul 2026
First PostedNov 13, 2014
Enrollment StartApr 28, 2015
Primary CompletionFeb 22, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.6 years ago
Interventions
nab-Paclitaxeldrug
Carboplatindrug